AAV-based gene therapy for X-linked retinitis pigmentosa

preview_player
Показать описание
Sue Washer, Applied Genetic Technologies Corporation, Alachua, FL, discusses the results of the Phase I/II and Phase II SKYLINE trials (NCT03316560) of a subretinal adeno-associated virus (AAV)-based gene therapy in patients with X-linked retinitis pigmentosa (XLRP). In the Phase I/II investigational portion of the trial, a majority of patients receiving a high dose reported an improvement in visual function and acuity, and in the SKYLINE trial, patients will receive further mobility tests to assess vision. An additional Phase III VISTA trial (NCT04850118) will be conducted to assess efficacy in another cohort. This interview took place at Meeting on the Mesa 2021.
  1. VJRegenMed
  2. Speaker: Sue Washer
  3. Institution: Applied Genetic Technologies Corporation
  4. Event: Meeting on the Mesa 2021
  5. Format: Interview
  6. Specialty: Ophthalmology
Рекомендации по теме
AAV-based gene therapy 0:02:03

AAV-based gene therapy for X-linked retinitis pigmentosa

Norrie2018 - Progress 1:46:16

Norrie2018 - Progress in Gene Therapy for X-linked Disorders

X linked RP 0:01:49

X linked RP

Genetics: L27-A, Gene 0:27:47

Genetics: L27-A, Gene Therapy: AAV Biology (Recommend 1.5x Speed)

Next gen AAV: 0:44:11

Next gen AAV: How Can Synthetic Capsids Tackle Gene Therapy Challenges

Atsena’s XLRS Gene 0:05:03

Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial

Retinitis Pigmentosa and 0:36:54

Retinitis Pigmentosa and X-linked Retinitis Pigmentosa featuring SparingVision

AAV Vector Shedding 0:58:30

AAV Vector Shedding Assay—Best Practices in Clinical Gene Therapy Method Development

Gene Therapy for 0:03:03

Gene Therapy for Inherited Retinal Diseases

Retinitis Pigmentosa and 0:29:05

Retinitis Pigmentosa and X-linked Retinitis Pigmentosa featuring Beacon Therapeutics

Gene Therapy for 0:20:34

Gene Therapy for Hemophilia: AAV Vector Gene Therapy Application to Hemophilia

AAV Vectors in 0:26:32

AAV Vectors in the Eye - Shannon Boye

Solutions for gene 0:18:38

Solutions for gene therapy using a deeper analytical characterization of AAV vector development

Directed Evolution of 0:55:51

Directed Evolution of Next-Generation AAV Vector Systems for Clinical Gene Therapy

Dave Schaffer (10/3/2015) 0:54:18

Dave Schaffer (10/3/2015) - Evolving New Synthetic Viruses: Sparking the Gene Therapy Revolution

Opportunities for Ocular 0:57:29

Opportunities for Ocular Gene Therapy

Syncona launches new 0:07:37

Syncona launches new gene therapy company Beacon Therapeutics

2022 NDF GNEM 0:43:43

2022 NDF GNEM Symposium with Katherine Koczwara: Developing An AAV Gene Therapy For GNEM: Part ll

Gene Therapy Basics 0:04:05

Gene Therapy Basics (2022 Update)

Retinitis Pigmentosa and 0:37:19

Retinitis Pigmentosa and X-linked Retinitis Pigmentosa featuring MeiraGTx

Strange discoveries: FDA 0:00:12

Strange discoveries: FDA Approved the Gene Therapy Called Luxturna to Cure... #shorts #science

X-Linked Myotubular Myopathy 0:02:58

X-Linked Myotubular Myopathy

Atsena Doses First 0:03:52

Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial

Leveraging Gene Therapy 0:52:12

Leveraging Gene Therapy to Achieve LongTerm Continuous or Controllable Expression of Biotherapeutics